Breast cancer resistance protein (BCRP) affected acquired resistance to gefitinib in a "never-smoked" female patient with advanced non-small cell lung cancer
Breast cancer resistance protein (BCRP) affected acquired resistance to gefitinib in a "never-smoked" female patient with advanced non-small cell lung cancer
复制标题
DOI：
10.1016/j.lungcan.2007.05.019
复制
发表时间：
2007-11-01
期刊：
影响因子：
5.3
通讯作者：
Kato, H.
中科院分区：
文献类型：
--
作者：
Usuda, J.;Ohira, T.;Kato, H.
在最初的良好反应后，对吉非替尼的获得性耐药性的发展是常见的。最近，据报道，这种获得性耐药性与表皮生长因子受体（EGFR）基因密码子790（T790 M）处苏氨酸被甲硫氨酸取代相关的继发突变有关。在这份报告中，我们提出了一个“从不吸烟”的晚期肺癌妇女谁表现出获得性耐药吉非替尼，尸检样本分析显示没有证据的EGFR突变，无论是外显子18-21或密码子790，和乳腺癌耐药蛋白（BCRP）的免疫染色阳性。我们首次描述了BCRP表达与吉非替尼获得性耐药相关的病例，与EGFR突变无关。(c)2007爱思唯尔爱尔兰有限公司保留所有权利。
Development of acquired resistance to gefitinib after an initial good response is common. Recently, it was reported that this acquired resistance is related to a secondary mutation associated with a substitution of threonine by methionine at codon 790 (T790M) of the epidermal growth factor receptor (EGFR) gene. In this report, we present a "never smoking" woman with advanced lung cancer who showed acquired resistance to gefitinib, and analysis of autopsy samples revealed no evidence of EGFR mutations in either exons 18-21 or codon 790, and positive immunostaining for breast cancer resistance protein (BCRP). We describe, for the first time, a case in which expression of BCRP was associated with acquired resistance to gefitinib, independent of EGFR mutations. (c) 2007 Elsevier Ireland Ltd. All rights reserved.